Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process by Kaltenthaler E et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Kaltenthaler E, Carroll C, Hill-McManus D, Scope A, Holmes M, Rice S, Rose M, 
Tappenden P, Woolacott N.  
Issues Related to the Frequency of Exploratory Analyses by Evidence Review 
Groups in the NICE Single Technology Appraisal Process.  
PharmacoEconomics Open 2017, 1(2), 99-108. 
 
 
Copyright: 
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which 
permits any noncommercial use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. 
DOI link to article: 
https://doi.org/10.1007/s41669-016-0001-4  
Date deposited:   
20/09/2017 
  
ORIGINAL RESEARCH ARTICLE
Issues Related to the Frequency of Exploratory Analyses
by Evidence Review Groups in the NICE Single Technology
Appraisal Process
Eva Kaltenthaler1 • Christopher Carroll1 • Daniel Hill-McManus2 •
Alison Scope1 • Michael Holmes1 • Stephen Rice3 • Micah Rose4 • Paul Tappenden1 •
Nerys Woolacott5
Published online: 4 November 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Background Evidence Review Groups (ERGs) critically
appraise company submissions as part of the National
Institute for Health and Care Excellence (NICE) Single
Technology Appraisal (STA) process. As part of their
critique of the evidence submitted by companies, the ERGs
undertake exploratory analyses to explore uncertainties in
the company’s model. The aim of this study was to explore
pre-defined factors that might influence or predict the
extent of ERG exploratory analyses.
Objective The aim of this study was to explore predefined
factors that might influence or predict the extent of ERG
exploratory analyses.
Methods We undertook content analysis of over 400 doc-
uments, including ERG reports and related documentation
for the 100 most recent STAs (2009–2014) for which
guidance has been published. Relevant data were extracted
from the documents and narrative synthesis was used to
summarise the extracted data. All data were extracted and
checked by two researchers.
Results Forty different companies submitted documents as
part of the NICE STA process. The most common disease
area covered by the STAs was cancer (44%), and most ERG
reports (n = 93) contained at least one exploratory analysis.
The incidence and frequency of ERG exploratory analyses
does not appear to be related to any developments in the
appraisal process, the disease area covered by the STA, or the
company’s base-case incremental cost-effectiveness ratio
(ICER). However, there does appear to be a pattern in the
mean number of analyses conducted by particular ERGs, but
the reasons for this are unclear and potentially complex.
Conclusions No clear patterns were identified regarding
the presence or frequency of exploratory analyses, apart
from the mean number conducted by individual ERGs.
More research is needed to understand this relationship.
Key Points for Decision Makers
As part of their critique of the evidence submitted by
companies in the National Institute for Health and
Care Excellence Single Technology Appraisal (STA)
process, the Evidence Review Groups (ERGs)
undertake exploratory analyses to explore
uncertainties.
Of the 100 STAs included in this analysis, 93 had
exploratory analyses undertaken by the ERG.
There is no clear pattern to the presence or frequency
of exploratory analyses; these cannot be obviously
explained by the disease area covered by the STA,
the time the STA took place, or the company’s base-
case incremental cost-effectiveness ratio.
There may be a pattern in the mean number of
analyses conducted by individual ERGs.
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1 Introduction
The UK National Institute for Health and Care Excellence
(NICE) Single Technology Appraisal (STA) process is
usually undertaken for a technology for a single indication
and includes the production of a submission by the man-
ufacturer or sponsor of the technology. NICE commissions
independent Evidence Review Groups (ERGs) to critically
appraise company submissions as part of the STA process.
In their critique of the evidence submitted by companies,
the ERGs often undertake exploratory analyses to explore
uncertainties around the company’s model and their
implications for decision making. The number and type of
exploratory analyses undertaken varies between appraisals.
The ERG reports are a central component of the evidence
considered by the NICE Technology Appraisal Committees
(AC) in forming their recommendations. The findings of
the committee are used to produce the Appraisal Consul-
tation Document (ACD) and, after further considerations
and a consultation period, a Final Appraisal Determination
(FAD) is produced, which results in NICE guidance. The
STA process is outlined in detail in NICE’s Guide to the
Process of Technology Appraisal [1]. The company is
expected to follow the decision-analytic approaches as
described in the Guide to the Methods of Technology
Appraisal [2], and the submission is expected to contain an
evaluation of the clinical effectiveness and cost effective-
ness of the technology. It is the responsibility of the ERG
to determine what additional analyses are required and to
undertake them, although they may be constrained by the
availability of data, the model structure, or time. The ERG
may also identify and correct technical or programming
errors. This critical appraisal of the company submission,
and any additional work as a consequence of this critical
appraisal, forms the basis of the ERG’s report. NICE’s
remit to the ERGs is not overly prescriptive, allowing
ERGs to use their acknowledged expertise and judgement
in the methods used to critically appraise company sub-
missions. This is appropriate due to the wide variation in
complexity and quality of the company submissions
received.
There are currently nine ERGs:
• BMJ Technology Assessment Group (BMJ-TAG), BMJ
Group.
• Centre for Reviews and Dissemination (CRD)/Centre
for Health Economics (CHE), University of York.
• Health Economics Research Unit and Health Services
Research Unit, University of Aberdeen.
• Kleijnen Systematic Reviews Ltd.
• Liverpool Reviews and Implementation Group (LRiG),
University of Liverpool.
• Peninsula Technology Assessment Group (PenTAG),
Peninsula Medical School, University of Exeter.
• School of Health and Related Research (ScHARR),
University of Sheffield.
• Southampton Health Technology Assessment Centre
(SHTAC), University of Southampton.
• Warwick Evidence, University of Warwick.
An additional ERG, the West Midlands Health Tech-
nology Assessment Collaboration, undertook STAs during
the period 2005–2010. ERGs are assigned to work on STAs
based on availability and lack of conflicts for specific
topics.
Some assessment of ERG report production process has
been undertaken. For example, Wong et al. [3] assessed
approaches used by ERGs to critically appraise search
strategies within company submissions. Previous research has
highlighted issues with company submissions that are par-
ticularly challenging to the ERGs [4]. Carroll et al. [5] sug-
gested that company STA submissions could be improved if
attention were paid to transparency in the reporting, conduct
and justification of the review, and modelling processes and
analyses, as well as greater robustness in the choice of data in
the model and closer adherence to the scope or decision
problem. Kaltenthaler et al. [6] also recommended the need
for clear and transparent reporting of company submissions,
and for a clear and concise rationale for the synthesis of
clinical data, the development of economic models and the
assumptions used to develop models.
The aim of this study was to note the number of
exploratory analyses undertaken by the ERGs within the
NICE STA process and to assess whether their frequency
might be explained by variables such as disease area or a
company’s base-case incremental cost-effectiveness ratio
(ICER). For the purpose of this research, an exploratory
analysis was defined as any additional analysis that gener-
ated an ICER and was included in the ERG report section
titled ‘Exploratory and sensitivity analyses undertaken by
the ERG’ (most commonly reported in Sect. 6 of the sug-
gested ERG report template). This is an underresearched area
and this study was commissioned by NICE to develop
understanding of this aspect of the STA process. This
research is of interest to all key stakeholders in the STA
process, including the ERGs, pharmaceutical companies,
AC members and NICE. The full research report forms part
of the National Institute for Health Research Health Tech-
nology Assessment (NIHR HTA) monograph series [7]. The
objectives of the study presented here were twofold.
1. To identify the extent of ERG exploratory analyses, as
defined above.
2. To identify factors that influence or predict the extent
of ERG exploratory analyses.
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2 Methods
This was a joint project undertaken by researchers from the
University of Sheffield and the University of York, all with
considerable experience of the NICE STA process. The
100 most recently completed STAs (2009–2014) for which
guidance has been published were selected for inclusion in
the analysis. A list of the STAs included in this analysis is
provided in Appendix 1. Data were extracted from over
400 separate documents associated with these STAs,
including ERG reports (unredacted versions, including
confidential information used by the ACs), the first ACD
issued and the final FAD issued.
A data extraction tool to extract relevant data to address
the project objectives was developed and piloted to ensure
usability and to standardise extraction [7]. The following
items were included in the data extraction form:
• basic characteristics including company, disease area
and ERG;
• company’s base-case ICER(s);
• number and type of exploratory analyses conducted by
the ERG.
All data extractions were double-checked by a second
researcher, and a narrative synthesis [8] of the extracted
data was performed, summarising key data through text
and tables to highlight any potentially important patterns or
relationships in the data. The mean and median numbers of
exploratory analyses per ERG report were calculated. The
mean number of analyses was used to provide a simple
binary variable with which to test some assumptions about
relationships between the number of exploratory analyses
and variables such as disease area and ICER. It was con-
sidered a priori that the disease area and an estimated cost-
effectiveness ratio of £20,000 per quality-adjusted life-year
(QALY) were the key variables potentially most likely to
predict the incidence and frequency of exploratory analy-
ses. This was due to the known impact of disease area on
other elements of STAs [9] and the perceived importance
of the £20,000 per QALY ICER for NICE decision making
[10]. An assessment was also made to identify any changes
in the number of exploratory analyses undertaken over
time, and whether the number and type of exploratory
analyses differed by the ERG undertaking the critical
appraisal. A more in-depth investigation of the types of
exploratory analyses undertaken, and their role and impact
on NICE decision making, is provided elsewhere [7].
The key data used in the synthesis were then reduced to
whether an STA conducted more or less than the overall
mean number of exploratory analyses, and whether just
‘one or more’ exploratory analyses were explicitly cited as
having an influence on a recommendation (defined as being
mentioned in the ACD or FAD). These arbitrary selections
were made as a means of making the most of the data to
address the objectives of the project and are explained
more fully elsewhere [7, 11].
3 Results
3.1 Overview of the 100 Single Technology
Appraisals
Forty different companies made submissions as part of the
NICE STA process. The companies with the largest number
of submissions were Roche (n = 16), Novartis (n = 9),
Glaxo Smith Kline (n = 7), Bristol-Meyers Squibb (n = 7)
and Bayer (n = 6). Other companies involved had five or
fewer submissions and the majority of companies made only
one or two submissions: Alimera Sciences, Alimta, Allergan,
Amgen, Astellas Pharma, Astra Zeneca, Biogen, Boehrin-
ger-Ingelheim, Celgene, Cell Therapeutics Inc., Eli Lilly,
Eliquis, Eisai, Genzyme, InterMune, Janssen, Laboratoires
Servier, Movetis, MSD, Napp, Novo Nordisk, Otsuka
Pharmaceuticals, Pfizer, PharmaMar, Pharmaxis, Pierre
Fabre, Sanofi Aventis, Savient Pharmaceuticals, Schering-
Plough, Stelara, Sucampo Pharma Europe, Takeda UK Ltd,
The Medicines Company, Thrombogenics, and UCB.
The principal disease areas covered by the STAs were
cancer (44%), blood and the immune system conditions
(11%), cardiovascular conditions (10%) and muscu-
loskeletal conditions (8%). Figure 1 shows a breakdown of
disease area by company. Cancer is clearly covered by
many companies, although Roche, GlaxoSmithKline and
Novartis have contributed the most STAs of this nature.
Roche and GlaxoSmithKline have both also contributed the
most blood and immune system STAs.
Most of the ERG reports contained at least one
exploratory analysis (93%), and a total of 40 (43%)
included eight or more such analyses. The mean number of
exploratory analyses per report containing exploratory
analyses was 8.5, with a median of 7 and a range of 1–29.
For this reason, a cut-off point of 8 exploratory analyses
was chosen for these analyses. Figure 2 shows the distri-
bution of exploratory analyses. With regard to the seven
ERG reports that did not include any exploratory analyses,
the majority (five ERG reports, 71%) stated that no
exploratory analyses were undertaken by the ERG as the
company models were considered to have serious flaws.
One ERG report stated that no exploratory analyses were
undertaken due to no ICERs being presented by the com-
pany (TA 191) [12], and one (TA 267) [13] because the
ERG was satisfied with the company model and the sen-
sitivity analyses presented by the company.
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3.2 Factors That May Have Influenced the Number
of Exploratory Analyses Undertaken
by the Evidence Review Group
Four variables that may influence the incidence and fre-
quency of exploratory analyses were considered:
• disease area;
• ICER;
• changes over time;
• the ERG undertaking the critical appraisal.
The incidence and frequency of ERG exploratory anal-
yses do not appear to be related to the disease area covered
by the STA (see Table 1). STAs in the blood/immune
system category did have a slightly higher proportion of
ERG reports, with more than eight exploratory analyses (7/
11, 64%) than the other disease areas. However, as most
disease area categories had small numbers of STAs, it is
difficult to draw any firm conclusions from this.
With regard to the estimated cost-effectiveness ratio,
there does not appear to be a relationship between the com-
pany’s base-case ICER and the incidence or number of
exploratory analyses (see Table 2). Of the 93 ERG reports
presenting one or more exploratory analyses, the proportion
of ERG reports in which the company’s base-case ICER was
below £20,000 per QALY gained was similar to the pro-
portion at or above this ICER (47 and 53%), and the pro-
portion of ERG reports below or above £30,000 per QALY
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gained shifts slightly but was also similar (54 and 46%). The
likelihood of an ERG performing eight or more exploratory
analyses did not appear to be affected by the company’s base-
case ICER. The proportion of ERG reports with eight or more
exploratory analyses was very similar in the STAs in which
the company base-case ICER was below £20,000 per QALY
gained (41%) or above this ICER (45%).
Developments in the STA process between 2009 and
2014 do not appear to have influenced the frequency of
exploratory analyses undertaken, as shown in Fig. 3. In this
sample, the total number of STAs undertaken has varied
from three in 2009 to 23 in 2011; however, the number of
ERG reports with eight or more exploratory analyses
appears to be largely consistent over time. For example,
between 2011 and 2014, the percentage was consistent in
each year and was always between 38 and 45%.
However, there does appear to be a possible pattern in
the mean number of analyses conducted by particular
ERGs, as shown in Table 3.
The University of York CRD/CHE produced the highest
number of reports (n = 18), while Warwick Evidence pro-
duced the fewest (n = 5). The number of reports varies
between the ERGs depending on how long they have been
undertaking STAs and the size of their agreed contract. The
ScHARR had the highest mean number of exploratory
analyses per report (11.4), while West Midlands had the
fewest (2.3). Of the ERGs currently involved in the STA
process, the teams with the lowest mean number of
exploratory analyses per report were Kleijnen Systematic
Reviews (5.3) and Liverpool Reviews (5.6). As stated above,
the number of exploratory analyses appears to be largely
consistent over time for the whole sample. We also looked at
the number of exploratory analyses by ERGs over time and
present data here for the ScHARR as an example. The other
ERGs showed similar results. The number of exploratory
analyses undertaken by the ScHARR appears to be the
highest and is quite stable over time. In 2011, the ScHARR
produced five ERG reports, and the number of exploratory
analyses ranged from 3 to 19; in 2012, the ScHARR pro-
duced three ERG reports, with the number of analyses
ranging from 2 to 22; and in 2013 two ERG reports were
produced, with 5 and 19 exploratory analyses. It therefore
appears that the number of exploratory analyses is likely to
be more dependent on the individual requirements of each
STA or other possible factors, rather than due to the ERG
becoming more rigorous in its critique (such that the number
of exploratory analyses might increase year-on-year) or
simply more focused (such that numbers of exploratory
analyses might decrease year-on-year).
4 Discussion
In this analysis, the vast majority (93%) of ERG reports
reported one or more exploratory analyses, with a mean of
8.5 exploratory analyses per report for the 93 reports where
Table 1 Number of reports by disease area with one or more, and
eight or more, exploratory analyses
Disease area Number of reports with
exploratory analyses
(n = 93)
Number of reports with
eight or more exploratory
analyses
Blood and
immune
system
11 (12) 7/11 (64)
Cancer 40 (43) 15/40 (38)
Cardiovascular 9 (10) 4/9 (40)
Central nervous
system
4 (4) 2/4 (50)
Digestive
system
2 (2) 0/2 (0)
Endocrine,
nutrition and
metabolic
3 (4) 1/3 (25)
Eye 7 (8) 4/7 (57)
Infectious
diseases
2 (2) 1/2 (50)
Mental health 2 (2) 1/2 (50)
Musculoskeletal 7 (8) 4/7 (50)
Respiratory 3 (3) 0/3 (0)
Therapeutic
procedures
2 (2) 1/2 (50)
Urogenital 1 (1) 0/1 (0)
Data are expressed as n (%)
Table 2 Number of reports by
company ICER with one or
more, or eight or more,
exploratory analyses
ICER Number of reports with one or more exploratory analysis
B£20,000 per QALY gained 44/93 (47)
[£20,000 per QALY gained 49/93 (53)
ICER Number of reports with eight or more exploratory analyses
B£20,000 per QALY gained 18/44 (41)
[£20,000 per QALY gained 22/49 (45)
Data are expressed as n (%)
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year
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exploratory analyses were undertaken. Of the 93 ERG
reports with at least one exploratory analysis, a total of 40
(43%) included eight or more such analyses. The likelihood
of an ERG performing eight or more exploratory analyses
does not appear to be affected by the disease area covered
by the STA or the company’s base-case ICER. In previous
research, Barham [9] analysed data from the first 18 STAs
undertaken by NICE and found 56% of these to cover
cancer topics. In an analysis of the first 4 years of the NICE
STA process, 48% of STAs were undertaken in cancer
topics [14], slightly higher than reported in this study. This
shows that the percentage of STAs that are cancer topics
may be decreasing over time.
The proportion of ERG reports with eight or more
analyses appears to be relatively stable over time and not
related to any developments in the process between 2009
and 2014. Although there have been changes to the NICE
technology appraisal process and methods guides during
this time period, these appear to have had little effect on the
number of exploratory analyses undertaken by the ERGs.
As shown in the example of the analysis of ScHARR data,
there does not appear to be a time-dependent trend as the
number of analyses undertaken by the ERG appears to be
stable with respect to time. Additional analyses of the data,
both from other ERGs and from pharmaceutical compa-
nies, show similar results (data not shown).
The number of exploratory analyses varied by ERG. For
the 10 ERGs undertaking STAs, the mean number of
exploratory analyses per report ranged from 2.3 (West
Midlands) to 11.4 (ScHARR). The reasons for this varia-
tion are unclear and potentially complex, and will include
such factors as how thoroughly the company has explored
the uncertainties and plausible alternative scenarios. It
should be noted that no regression analyses were performed
to explore the relationship between the mean number of
analyses per report and variables such as ERG, disease area
or year due to the limitations of the data because there was
only one independent variable in any category (cancer in
disease area) that exceeded 20 in number, with the majority
being very small numbers, and with the result being that
any such analysis would be underpowered. Other poten-
tially influential factors, such as the complexity and per-
ceived quality of company submissions, were also not
explored or analysed. Therefore, this finding should be
interpreted with caution and more research is needed to
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Table 3 ERGs responsible for producing reports within STAs
included in the analysis
ERG Number
of reports
Number of
analyses/
number
of reports
Mean number
of exploratory
analyses per report
Aberdeen 11 72/11 6.5
BMJ 8 83/8 10.4
Kleijnen
Reviews
7 37/7 5.3
Liverpool
(LRiG)
17 96/17 5.6
PenTAG 4 38/4 9.5
ScHARR 13 148/13 11.4
Southampton 10 91/10 9.1
Warwick 5 44/5 8.8
West Midlands 7 16/7 2.3
York CRD/CHE 18 173/18 9.6
Total 100 798/100 8
ERGs Evidence Review Groups, STAs Single Technology Appraisals,
LRiG Liverpool Reviews and Implementation Group, PenTAG
Peninsula Technology Assessment Group, ScHARR School of Health
and Related Research, CRD Centre for Reviews and Dissemination,
CHE Centre for Health Economics
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determine the relationship between variables such as ERG
and number of exploratory analyses undertaken, which
may also vary according to the skills, experience and
judgements of the ERGs and that of individuals within the
ERGs. This issue was not explored within this study.
Only seven of the STAs included in this analysis had no
exploratory analyses undertaken by the ERGs, principally
due to serious flaws identified by the ERG in the company
model, which would have rendered analyses irrelevant. In
only one of the STAs were no exploratory analyses
undertaken by the ERG because the ERG was satisfied with
the model and analyses presented by the company. The
exploratory analyses undertaken by the ERGs serve various
functions: to correct errors and violations within the com-
pany’s model; to address uncertainties in the evidence
base; and explore a range of plausible scenarios, and
therefore support NICE AC decision making. The
exploratory analyses undertaken by ERGs frequently
influence both ACD and FAD recommendations [11].
This analysis is a good reflection of current practice as
the most recent 100 STAs were included. The data
extraction tool was extensively piloted and the double-
checking of all key data across the 100 STAs by at least
two experienced cost-effectiveness modellers reduced the
likelihood of inconsistency and inaccuracy in the data. The
use of narrative synthesis was principally descriptive, and
reduced the likelihood of overstating relationships in the
data. A reductive approach was taken to managing data that
might be affected by interpretation or by poor reporting in
the original documents. However, there are some limita-
tions to this research. The descriptions of analyses under-
taken were often highly specific to a particular STA and
could be inconsistent across ERG reports, and thus difficult
to interpret and categorise. In addition, small inconsisten-
cies might have affected the data extraction, which may be
due to several people being involved. A number of other
factors not considered in this study may have influenced
the number of exploratory analyses undertaken by the
ERGs but this was beyond the remit of this research.
This analysis of over 400 documents provides an over-
view of some of the principal factors potentially affecting
the number of exploratory analyses undertaken by the
ERGs. The wider study reported that four types of
exploratory analysis were conducted in relation to com-
panies’ models: fixing errors; addressing violations;
addressing matters of judgement; and the provision of a
new, ERG-preferred base-case. Ninety-three of the 100
ERG reports contained at least one of these analyses, and
the most frequently reported type of analysis related to the
category ‘matters of judgement’. The results of the wider
study also suggest that these additional analyses under-
taken by ERGs were highly influential in the policy and
decision-making process [7, 11]. More in-depth analysis is
needed to understand how ERGs make decisions regarding
the exploratory analyses to be undertaken. More research is
also needed to fully understand the types of exploratory
analyses most useful to ACs in their decision making.
5 Conclusions
There is no clear pattern to the presence or frequency of
exploratory analyses; they do not appear to be predicted by
the disease area covered by the STA, the time the STA took
place, or the company’s base-case ICER. In addition, there
does appear to be a pattern in the mean number of analyses
conducted by individual ERGs, but more research is nee-
ded to understand this relationship.
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Appendix 1: 100 included STAs
NICE TA
number
Full appraisal title
TA181 Pemetrexed for the first-line treatment of non-small-cell lung cancer
TA182 Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention
TA183 Topotecan for the treatment of recurrent and stage IVB cervical cancer
TA185 Trabectedin for the treatment of advanced soft tissue sarcoma
TA186 Certolizumab pegol for the treatment of rheumatoid arthritis
TA189 Sorafenib for the treatment of advanced hepatocellular carcinoma
TA190 Pemetrexed for the maintenance treatment of non-small-cell lung cancer
TA191 Capecitabine for the treatment of advanced gastric cancer
TA192 Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
TA193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
TA196 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
TA197 Dronedarone for the treatment of non-permanent atrial fibrillation
TA198 Tocilizumab for the treatment of rheumatoid arthritis
TA201 Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 years
TA202 Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab
TA203 Liraglutide for the treatment of type 2 diabetes mellitus
TA204 Denosumab for the prevention of osteoporotic fractures in postmenopausal women
TA205 Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura
TA208 Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
TA211 Prucalopride for the treatment of chronic constipation in women
TA212 Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of
metastatic colorectal cancer
TA213 Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years
TA214 Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
TA215 Pazopanib for the first-line treatment of advanced renal cell carcinoma
TA216 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
TA218 Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
TA219 Everolimus for the second-line treatment of advanced renal cell carcinoma
TA220 Golimumab for the treatment of psoriatic arthritis
TA221 Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura
TA222 Trabectedin for the treatment of relapsed ovarian cancer
TA225 Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
TA226 Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
TA227 Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
TA229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
TA230 Bivalirudin for the treatment of ST-segment-elevation myocardial infarction
TA232 Retigabine for the adjunctive treatment of partial onset seizures in epilepsy
TA233 Golimumab for the treatment of ankylosing spondylitis
TA234 Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs
TA235 Mifamurtide for the treatment of osteosarcoma
TA236 Ticagrelor for the treatment of acute coronary syndromes
TA237 Ranibizumab for the treatment of diabetic macular oedema
TA238 Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
TA239 Fulvestrant for the treatment of locally advanced or metastatic breast cancer
TA244 Roflumilast for the management of severe chronic obstructive pulmonary disease
TA245 Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
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TA248 Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2
diabetes
TA249 Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
TA250 Eribulin for the treatment of locally advanced or metastatic breast cancer
TA252 Telaprevir for the treatment of genotype 1 chronic hepatitis C
TA253 Boceprevir for the treatment of genotype 1 chronic hepatitis C
TA254 Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
TA255 Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen
TA256 Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
TA258 Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
TA259 Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
TA260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
TA261 Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary
embolism
TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
TA264 Alteplase for treating acute ischaemic stroke
TA266 Mannitol dry powder for inhalation for treating cystic fibrosis
TA267 Ivabradine for treating chronic heart failure
TA268 Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
TA269 Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
TA271 Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response
to prior therapy
TA272 Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract
TA275 Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
TA282 Pirfenidone for treating idiopathic pulmonary fibrosis
TA283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
TA284 Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
TA285 Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced
ovarian cancer
TA287 Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced
ovarian cancer
TA288 Dapagliflozin in combination therapy for treating type 2 diabetes
TA289 Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis
TA290 Mirabegron for treating symptoms of overactive bladder
TA291 Pegloticase for treating severe debilitating chronic tophaceous gout
TA292 Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder
TA293 Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura
TA294 Aflibercept solution for injection for treating wet age-related macular degeneration
TA295 Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer
after endocrine therapy
TA296 Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene
TA297 Ocriplasmin for treating vitreomacular traction
TA298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
TA299 Bosutinib for previously treated chronic myeloid leukaemia
TA303 Teriflunomide for treating relapsing–remitting multiple sclerosis
TA305 Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
TA306 Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma
TA307 Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has
progressed following prior oxaliplatin-based chemotherapy
TA308 Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
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TA309 Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-
cell lung cancer
TA310 Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung
cancer
TA311 Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell
transplantation
TA312 Alemtuzumab for treating relapsing-remitting multiple sclerosis
TA313 Ustekinumab for treating active psoriatic arthritis
TA315 Canagliflozin in combination therapy for treating type 2 diabetes
TA316 Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen
TA318 Lubiprostone for treating chronic idiopathic constipation
TA319 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
TA320 Dimethyl fumarate for treating relapsing-remitting multiple sclerosis
TA321 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
TA322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
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